<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dercle L</submitter><funding>NCI NIH HHS</funding><pagination>1-8</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6874047</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>1</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>New response patterns to anticancer drugs have led tumor size-based response criteria to shift to also include density measurements. Choi criteria, for instance, categorize antiangiogenic therapy response as a decrease in tumor density > 15% at the portal venous phase (PVP). We studied the effect that PVP timing has on measurement of the density of liver metastases (LM) from colorectal cancer (CRC).&lt;h4>Methods&lt;/h4>Pretreatment PVP computed tomography images from 291 patients with LM-CRC from the CRYSTAL trial (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer; ClinicalTrials.gov identifier: NCT00154102) were included. Four radiologists independently scored the scans' timing according to a three-point scoring system: early, optimal, la</pubmed_abstract><journal>JCO clinical cancer informatics</journal><pubmed_title>Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm.</pubmed_title><pmcid>PMC6874047</pmcid><funding_grant_id>U01 CA140207</funding_grant_id><pubmed_authors>Yang H</pubmed_authors><pubmed_authors>Lu L</pubmed_authors><pubmed_authors>Piessevaux H</pubmed_authors><pubmed_authors>Schwartz LH</pubmed_authors><pubmed_authors>Dercle L</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Zhao B</pubmed_authors><pubmed_authors>Lichtenstein P</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Wu F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm.</name><description>&lt;h4>Purpose&lt;/h4>New response patterns to anticancer drugs have led tumor size-based response criteria to shift to also include density measurements. Choi criteria, for instance, categorize antiangiogenic therapy response as a decrease in tumor density > 15% at the portal venous phase (PVP). We studied the effect that PVP timing has on measurement of the density of liver metastases (LM) from colorectal cancer (CRC).&lt;h4>Methods&lt;/h4>Pretreatment PVP computed tomography images from 291 patients with LM-CRC from the CRYSTAL trial (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer; ClinicalTrials.gov identifier: NCT00154102) were included. Four radiologists independently scored the scans' timing according to a three-point scoring system: early, optimal, la</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Nov</publication><modification>2025-04-04T03:27:08.899Z</modification><creation>2020-05-21T21:10:03Z</creation></dates><accession>S-EPMC6874047</accession><cross_references><pubmed>30657405</pubmed><doi>10.1200/cci.17.00108</doi><doi>10.1200/CCI.17.00108</doi></cross_references></HashMap>